COMP <GO>
IBRX vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
ImmunityBio Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: IBRX 3
— UNH 10
■ METRIC PARITY
LAST: $7.95 (-4.10%) • MKT CAP: $8.79B
options-implied-move
—
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
options-implied-move
7.11%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 11.47% | -38.77 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 6.47% | -9.80 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.46% | +173.54 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 3.12 | -2.67 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 57.4 | -13.10 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 17.7x | +11.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.79B | $365.29B | -$356.51B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | UNH REV | IBRX GROSS % | UNH GROSS % | IBRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $447.57B | 99.3% | 88.7% | -$308.8M | $16.07B |
| FY 2024 | $14.7M | $400.28B | 100.0% | 88.3% | -$398.1M | $20.70B |
| FY 2023 | $622.0K | $371.62B | — | 89.6% | -$366.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
UNH // BETA 0.33